^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DDR enhancer

    Related drugs:
    18d
    TOPOLOGY: A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=14, Terminated, Institut Curie | N=44 --> 14 | Trial completion date: Apr 2027 --> May 2025 | Recruiting --> Terminated | Trial primary completion date: Apr 2027 --> May 2025; No signal of significant toxicity and no signal of activity in the population of the TOPOLGY study
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    PLX038
    18d
    POP-ART: A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=10, Terminated, Institut Curie | N=92 --> 10 | Trial completion date: Sep 2029 --> Nov 2025 | Recruiting --> Terminated | Trial primary completion date: Sep 2028 --> Nov 2025; Although no safety signal has been observed, given that the industrial development of tuvusertib has been halted regardless of the results, we see no scientific and ethical justification for continuing the study
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    PLX038 • tuvusertib (M1774)
    8ms
    TOPOLOGY: A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=44, Recruiting, Institut Curie | Trial completion date: Mar 2026 --> Apr 2027 | Trial primary completion date: Aug 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    PLX038
    11ms
    POP-ART: A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=92, Recruiting, Institut Curie | Trial primary completion date: Sep 2027 --> Sep 2028
    Trial primary completion date
    |
    PLX038 • tuvusertib (M1774)
    11ms
    POP-ART: A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=92, Recruiting, Institut Curie | Not yet recruiting --> Recruiting | Trial completion date: Feb 2029 --> Sep 2029 | Initiation date: Jun 2024 --> Jan 2025 | Trial primary completion date: Jun 2025 --> Sep 2027
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    PLX038 • tuvusertib (M1774)
    over1year
    PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=43, Recruiting, Mayo Clinic | Trial completion date: Feb 2025 --> Dec 2031 | Trial primary completion date: Feb 2025 --> May 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    PLX038 • firtecan pegol (PEG-SN38)
    over1year
    TOPOLOGY: A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=44, Recruiting, Institut Curie | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PLX038
    almost2years
    POP-ART: A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=92, Not yet recruiting, Institut Curie
    New P1 trial • Combination therapy • Metastases
    |
    PLX038 • tuvusertib (M1774)
    2years
    PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications (clinicaltrials.gov)
    P1/2, N=120, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    PLX038
    2years
    PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=43, Recruiting, Mayo Clinic | Trial primary completion date: Feb 2024 --> Feb 2025
    Trial primary completion date • Metastases
    |
    ABCG2 expression
    |
    PLX038 • firtecan pegol (PEG-SN38)
    2years
    TOPOLOGY: A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Institut Curie
    New P2 trial
    |
    PLX038
    2years
    PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications (clinicaltrials.gov)
    P1/2, N=120, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    PLX038